2.6.1.83: LL-diaminopimelate aminotransferase
This is an abbreviated version!
For detailed information about LL-diaminopimelate aminotransferase, go to the full flat file.
Word Map on EC 2.6.1.83
-
2.6.1.83
-
chlamydia
-
tetrahydrodipicolinate
-
l-lysine
-
meso-diaminopimelate
-
peptidoglycan
-
trachomatis
-
verrucomicrobium
-
spinosum
-
herbicide
-
pyridoxal-5'-phosphate
-
auxotrophic
-
cyanobacteria
-
plp-dependent
-
aminotransferases
-
l-glutamate
-
reinhardtii
-
pyridoxal
-
transamination
-
chlamydomonas
-
v-shaped
-
hydrazide
-
algaecide
-
thermautotrophicus
-
meso-dap
-
methanothermobacter
-
methanococcales
-
methanogens
-
rhodanine
-
drug development
-
leptospira
- 2.6.1.83
- chlamydia
- tetrahydrodipicolinate
- l-lysine
- meso-diaminopimelate
- peptidoglycan
- trachomatis
-
verrucomicrobium
- spinosum
-
herbicide
- pyridoxal-5'-phosphate
-
auxotrophic
- cyanobacteria
-
plp-dependent
- aminotransferases
- l-glutamate
- reinhardtii
- pyridoxal
-
transamination
-
chlamydomonas
-
v-shaped
- hydrazide
-
algaecide
- thermautotrophicus
-
meso-dap
-
methanothermobacter
- methanococcales
-
methanogens
- rhodanine
- drug development
- leptospira
Reaction
Synonyms
Ald1, aq_273, AtDAP-AT, Ava_1277, Ava_2354, BF2666, CT390, CtDAP-AT, Cthe_0816, DAP, DapI, DapL, Dhaf_1761, diaminopimelate aminotransferase, glr4108, GSU0162, L,L-diaminopimelate aminotransferase, LIC12841, LL-DAP aminotransferase, LL-DAP-AT, LL-DAPAT, LL-diaminopimelate aminotransferase, MA1712, Moth_0889, Msp_0924, MTH52, pc0685, Sfum_0054, sll0480, VsDapL
ECTree
Advanced search results
Inhibitors
Inhibitors on EC 2.6.1.83 - LL-diaminopimelate aminotransferase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
(2-[(E)-[1-(4-chlorophenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
-
14% inhibition at 0.01 mM
(2-[(E)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
(2-[(E)-[1-methyl-3-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
-
17% inhibition at 0.01 mM
(2E)-2-cyano-3-[5-(dimethylamino)furan-2-yl]-N-(3,4-dimethylphenyl)prop-2-enamide
-
14% inhibition at 0.01 mM
(2Z)-N'-nitro-2-[[5-(3-nitrophenyl)furan-2-yl]methylidene]hydrazinecarboximidamide
-
13% inhibition at 0.01 mM
(3E)-1-[(4-methoxyphenyl)sulfonyl]-3-[4-oxo-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-5-ylidene]-1,3-dihydro-2H-indol-2-one
-
18% inhibition at 0.01 mM
(3E)-1-[(4-methylphenyl)sulfonyl]-3-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)-1,3-dihydro-2H-indol-2-one
-
25% inhibition at 0.01 mM
(3E)-3-[2-(2,4-dimethyl-1,3-thiazol-5-yl)-2-oxoethylidene]-3,4-dihydroquinoxalin-2(1H)-one
-
18% inhibition at 0.01 mM
(3E)-3-[2-oxo-2-(thiophen-2-yl)ethylidene]-3,4-dihydroquinoxalin-2(1H)-one
-
15% inhibition at 0.01 mM
(3Z)-3-(2,4-dimethoxybenzylidene)-5-phenylfuran-2(3H)-one
-
14% inhibition at 0.01 mM
(5E)-5-(1H-indol-2-ylmethylidene)-1-(4-methylphenyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
16% inhibition at 0.01 mM
(5E)-5-[(1-benzyl-1H-indol-2-yl)methylidene]-1-(2-methoxyphenyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
20% inhibition at 0.01 mM
(5E)-5-[(1-methyl-1H-indol-2-yl)methylidene]-1-(prop-2-en-1-yl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
35% inhibition at 0.01 mM
(5E)-5-[(1-methyl-1H-indol-2-yl)methylidene]-1-prop-2-en-1-yl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
45% inhibition at 0.01 mM
(5E)-5-[[1-(4-nitrobenzyl)-1H-indol-2-yl]methylidene]-1-(prop-2-en-1-yl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
33% inhibition at 0.01 mM
(5Z)-1-(3-bromophenyl)-5-(furan-2-ylmethylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
17% inhibition at 0.01 mM
(5Z)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-5-[[1-phenyl-3-(thiophen-2-yl)-1H-pyrazol-4-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
13% inhibition at 0.01 mM
(5Z)-5-(3-iodo-4-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
29% inhibition at 0.01 mM
(5Z)-5-[(3-methylthiophen-2-yl)methylidene]-3-(1-phenylethyl)-2-thioxo-1,3-thiazolidin-4-one
-
13% inhibition at 0.01 mM
(5Z)-5-[(3-methylthiophen-2-yl)methylidene]-3-(tetrahydrofuran-2-ylmethyl)-2-thioxo-1,3-thiazolidin-4-one
-
14% inhibition at 0.01 mM
(5Z)-5-[(6-bromo-1,3-benzodioxol-5-yl)methylidene]-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
13% inhibition at 0.01 mM
(5Z)-5-[[5-(2-bromo-4-nitrophenyl)furan-2-yl]methylidene]-2-imino-1,3-thiazolidin-4-one
-
13% inhibition at 0.01 mM
(5Z)-5-[[5-(3-chlorophenyl)furan-2-yl]methylidene]-1-(4-methoxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
20% inhibition at 0.01 mM
(Z)-N -(5-((5-(4-nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetamide
-
-
(Z)-N-(5-(4-methoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetamide
-
-
1,3-bis((7-chloro-4-quinolinyl)amino)-2-propanol
-
NSC_5485, potential drug candidate that can inhibit the enzymatic activity of enzyme CtDAP-AT
1,3-dimethyl-5-[[1-(3-nitrophenyl)-1H-pyrrol-2-yl]methylidene]pyrimidine-2,4,6(1H,3H,5H)-trione
-
13% inhibition at 0.01 mM
1-(4-fluorophenyl)-2-[[4-phenyl-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazol-3-yl]sulfanyl]ethanone
-
14% inhibition at 0.01 mM
2-(2-[(E)-[1-(4-fluorophenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)-N-phenylacetamide
-
18% inhibition at 0.01 mM
2-thioxo-5-[(1,2,5-trimethyl-1H-pyrrol-3-yl)methylidene]dihydropyrimidine-4,6(1H,5H)-dione
2-[(2E)-2-(2-oxo-5-phenylfuran-3(2H)-ylidene)hydrazinyl]benzoic acid
-
16% inhibition at 0.01 mM
2-[2-[(E)-(4,6-dioxo-1-phenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-indol-1-yl]-N-phenylacetamide
3-cyclopropyl-N'-[(1E)-1-(4-methylphenyl)ethylidene]-1H-pyrazole-5-carbohydrazide
-
14% inhibition at 0.01 mM
3-[2-[(4-acetylphenyl)amino]-1,3-thiazol-4-yl]-2H-chromen-2-one
-
16% inhibition at 0.01 mM
4-chloro-N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
4-fluoro-N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
4-[(E)-[2-(2-chlorophenyl)-5-oxo-1,3-oxazol-4(5H)-ylidene]methyl]-2-hydroxyphenyl 2-chlorobenzoate
-
30% inhibition at 0.01 mM
5-(4-methylphenyl)-4-[[(E)-(2,4,5-trimethoxyphenyl)methylidene]amino]-4H-1,2,4-triazole-3-thiol
-
18% inhibition at 0.01 mM
5-([1-[2-(3,4-dimethylphenoxy)ethyl]-1H-indol-2-yl]methylidene)pyrimidine-2,4,6(1H,3H,5H)-trione
-
28% inhibition at 0.01 mM
5-[(5-hydroxy-1-phenyl-1H-pyrazol-4-yl)methylidene]-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione
-
20% inhibition at 0.01 mM
5-[3-[(2-chlorobenzyl)oxy]-4-methoxybenzylidene]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
48% inhibition at 0.01 mM
8-methoxy-3-[(2-methylprop-2-en-1-yl)oxy]-6H-benzo[c]chromen-6-one
-
25% inhibition at 0.01 mM
ethyl (5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-2-[(4-methoxyphenyl)amino]-4-oxo-4,5-dihydrothiophene-3-carboxylate
-
22% inhibition at 0.01 mM
ethyl (5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-2-[(4-nitrophenyl)amino]-4-oxo-4,5-dihydrothiophene-3-carboxylate
-
19% inhibition at 0.01 mM
ethyl 4-(5-[(Z)-[2,4,6-trioxo-1-(prop-2-en-1-yl)tetrahydropyrimidin-5(2H)-ylidene]methyl]furan-2-yl)benzoate
-
16% inhibition at 0.01 mM
N'-[(E)-(2,4-dihydroxyphenyl)methylidene]-5-nitro-3-phenyl-1H-indole-2-carbohydrazide
-
15% inhibition at 0.01 mM
N'-[(Z)-(4-fluorophenyl)methylidene]-3-(naphthalen-2-yl)-1H-pyrazole-5-carbohydrazide
-
14% inhibition at 0.01 mM
N-[(2E,5Z)-5-[[5-(4-nitrophenyl)furan-2-yl]methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]acetamide
-
52% inhibition at 0.01 mM
N-[(5E)-5-[(5-bromofuran-2-yl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetamide
-
13% inhibition at 0.01 mM
N-[(5Z)-5-[(5-bromofuran-2-yl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetamide
-
-
N-[2-(hydrazinylcarbonyl)-5-(trifluoromethyl)phenyl]benzenesulfonamide
-
-
N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-3-nitrobenzenesulfonamide
-
13% inhibition at 0.01 mM
N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]-4-methoxybenzenesulfonamide
-
-
N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]-4-methylbenzenesulfonamide
-
-
N-[[2-(2-chlorophenyl)-1,3-benzoxazol-5-yl]carbamothioyl]-3-methyl-1-benzofuran-2-carboxamide
-
19% inhibition at 0.01 mM
(2-[(E)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
-
(2-[(E)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
-
(2-[(E)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
WP_009961032
-
-
13% inhibition at 0.01 mM
(5Z)-5-[5-(2-chlorobenzyl)-2-hydroxybenzylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
(5Z)-5-[5-(2-chlorobenzyl)-2-hydroxybenzylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
(5Z)-5-[5-(2-chlorobenzyl)-2-hydroxybenzylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
WP_009961032
-
-
15% inhibition at 0.01 mM
2-thioxo-5-[(1,2,5-trimethyl-1H-pyrrol-3-yl)methylidene]dihydropyrimidine-4,6(1H,5H)-dione
-
2-thioxo-5-[(1,2,5-trimethyl-1H-pyrrol-3-yl)methylidene]dihydropyrimidine-4,6(1H,5H)-dione
-
2-thioxo-5-[(1,2,5-trimethyl-1H-pyrrol-3-yl)methylidene]dihydropyrimidine-4,6(1H,5H)-dione
WP_009961032
-
2-[2-[(E)-(4,6-dioxo-1-phenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-indol-1-yl]-N-phenylacetamide
-
2-[2-[(E)-(4,6-dioxo-1-phenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-indol-1-yl]-N-phenylacetamide
-
-
33% inhibition at 0.01 mM
N-[3-(hydrazinylcarbonyl)naphthalen-2-yl]benzenesulfonamide
-
N-[3-(hydrazinylcarbonyl)naphthalen-2-yl]benzenesulfonamide
WP_009961032
-
-
not inhibitory: m-diaminopimelate, lysine, ornithine
-
additional information
not inhibitory: m-diaminopimelate, lysine, ornithine
-
additional information
-
not inhibited by (Z)-5-benzylidene-2-thioxothiazolidin-4-one, (Z)-5-(naphthalen-1-ylmethylene)-2-thioxothiazolidin-4-one, (Z)-3-amino-5-benzylidene-2-thioxothiazolidin-4-one, (Z)-3-amino-5-(4-chlorobenzylidene)-2-thioxothiazolidin-4-one, (Z)-N-(5-benzylidene-4-oxo-2-thioxothiazolidin-3-yl)-acetamide, (Z)-N-(5-(4-chlorobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetamide, and (Z)-5-(2-nitrobenzylidene)-2-thioxothiazolidin-4-one
-
additional information
-
high-throughput virtual screening for potential enzyme inhibitors using the optimized and corrected PLP-bound L,Ldiaminopimelate aminotransferase structure based on the crystal structure, PDB ID 3ASB. Comparative molecular dynamics simulation studies of enzyme CtDAP-AT in apoform and in complex with potential inhibitors, intermolecular interaction profiling of the compounds in complex with CtDAP-AT
-
additional information
comprehensive inhibition study comparing the kinetic activity of DapL orthologs using small molecule inhibitors and recombinant enzymes from Leptospira interrogans, Verrucomicrobium spinosum and Chlamydomonas reinhardtii. Enzyme active sites are conserved, although the second shell of residues close to the active site are not. The enzymes respond differently to the inhibitors
-
additional information
-
comprehensive inhibition study comparing the kinetic activity of DapL orthologs using small molecule inhibitors and recombinant enzymes from Leptospira interrogans, Verrucomicrobium spinosum and Chlamydomonas reinhardtii. Enzyme active sites are conserved, although the second shell of residues close to the active site are not. The enzymes respond differently to the inhibitors
-
additional information
comprehensive inhibition study comparing the kinetic activity of DapL orthologs using small molecule inhibitors and recombinant enzymes from Leptospira interrogans, Verrucomicrobium spinosum and Chlamydomonas reinhardtii. Enzyme active sites are conserved, although the second shell of residues close to the active site are not. the enzymes respond differntly to the inhibors
-
additional information
-
comprehensive inhibition study comparing the kinetic activity of DapL orthologs using small molecule inhibitors and recombinant enzymes from Leptospira interrogans, Verrucomicrobium spinosum and Chlamydomonas reinhardtii. Enzyme active sites are conserved, although the second shell of residues close to the active site are not. the enzymes respond differntly to the inhibors
-
additional information
WP_009961032
comprehensive inhibition study comparing the kinetic activity of DapL orthologs using small molecule inhibitors and recombinant enzymes from Leptospira interrogans, Verrucomicrobium spinosum and Chlamydomonas reinhardtii. Enzyme active sites are conserved, although the second shell of residues close to the active site are not. The enzymes respond differently to the inhibitors. 2-[2-[(E)-(4,6-dioxo-1-phenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-indol-1-yl]-N-phenylacetamide is not inhibitory with Verrucomicrobium spinosum DapL
-
additional information
-
comprehensive inhibition study comparing the kinetic activity of DapL orthologs using small molecule inhibitors and recombinant enzymes from Leptospira interrogans, Verrucomicrobium spinosum and Chlamydomonas reinhardtii. Enzyme active sites are conserved, although the second shell of residues close to the active site are not. The enzymes respond differently to the inhibitors. 2-[2-[(E)-(4,6-dioxo-1-phenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-indol-1-yl]-N-phenylacetamide is not inhibitory with Verrucomicrobium spinosum DapL
-
additional information
rhodanine, barbiturate, hydrazide, and thiobarbiturate associations with VsDapL are supported by molecular dynamics simulations, docking study, overview
-
additional information
-
rhodanine, barbiturate, hydrazide, and thiobarbiturate associations with VsDapL are supported by molecular dynamics simulations, docking study, overview
-